Drug Type Small molecule drug |
Synonyms |
Mechanism Bcr-Abl inhibitors(Bcr-Abl tyrosine kinase inhibitors), EphA2 antagonists(Ephrin type-A receptor 2 antagonists), PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors) + [2] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | NDA/BLA | US | 23 Sep 2022 |